Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 11, 2026, 7:51 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 169–192 of 20,848 matching trials from the live ClinicalTrials.gov search.
Conditions
Common Warts, Common Warts (Verruca Vulgaris), Human Papilloma Virus (HPV), Warts
Interventions
VP-102, Vehicle
Combination Product
Lead sponsor
Verrica Pharmaceuticals Inc.
Industry
Eligibility
2 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
6
States / cities
Saint Augustine, Florida • Plainfield, Indiana • Hunt Valley, Maryland + 3 more
Recruiting Not applicable Interventional

SELUTION4BTK Trial

NCT05055297
Conditions
Peripheral Arterial Disease, Chronic Limb-Threatening Ischemia Nos of Native Arteries of Extremities
Interventions
SELUTION SLR™ DEB 014, Plain (Uncoated) Balloon Angioplasty (PTA)
Device
Lead sponsor
M.A. Med Alliance S.A.
Industry
Eligibility
18 Years and older
Enrollment
376 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2032
U.S. locations
30
States / cities
Chandler, Arizona • Jonesboro, Arkansas • Little Rock, Arkansas + 26 more
Conditions
Pulmonary Arterial Hypertension
Interventions
Macitentan, Standard-of-care
Drug · Other
Lead sponsor
Actelion
Industry
Eligibility
1 Month to 17 Years
Enrollment
165 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
20
States / cities
Phoenix, Arizona • Los Angeles, California • San Francisco, California + 17 more
Conditions
Locally Advanced Bladder Urothelial Carcinoma, Locally Advanced Renal Pelvis Urothelial Carcinoma, Locally Advanced Ureter Urothelial Carcinoma, Locally Advanced Urethral Urothelial Carcinoma, Metastatic Bladder Urothelial Carcinoma, Metastatic Renal Pelvis Urothelial Carcinoma, Metastatic Ureter Urothelial Carcinoma, Metastatic Urethral Urothelial Carcinoma, Recurrent Bladder Urothelial Carcinoma, Recurrent Renal Pelvis Urothelial Carcinoma, Recurrent Ureter Urothelial Carcinoma, Recurrent Urethral Urothelial Carcinoma, Stage III Bladder Cancer AJCC v8, Stage III Renal Pelvis Cancer AJCC v8, Stage III Ureter Cancer AJCC v8, Stage III Urethral Cancer AJCC v8, Stage IV Bladder Cancer AJCC v8, Stage IV Renal Pelvis Cancer AJCC v8, Stage IV Ureter Cancer AJCC v8, Stage IV Urethral Cancer AJCC v8, Unresectable Bladder Urothelial Carcinoma, Unresectable Renal Pelvis Urothelial Carcinoma, Unresectable Ureter Urothelial Carcinoma, Unresectable Urethral Urothelial Carcinoma
Interventions
Atezolizumab, Biopsy Procedure, Biospecimen Collection, Computed Tomography with Contrast, Eribulin Mesylate
Drug · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
21
States / cities
Birmingham, Alabama • Buena Park, California • Duarte, California + 15 more
Conditions
Non Small Cell Lung Cancer
Interventions
Alirocumab, Cemiplimab, Chemotherapy
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Durham, North Carolina
Conditions
Breast Cancer, Social Determinants of Health (SDOH)
Interventions
Early Point-of-Service Social and Behavioral Determinants of Health (SBDOH) Screening
Other
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
2,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Lymphoma
Interventions
milatuzumab, veltuzumab, Correlative/Special Studies, Quantitative T-, B-, and NK cell subsets, Pharmacokinetics, Human Anti-Human Antibodies, veltuzumab and milatuzumab
Biological · Procedure
Lead sponsor
Beth Christian
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
1
States / cities
Columbus, Ohio
Conditions
Lymphoma
Interventions
rituximab, bortezomib, carboplatin, dexamethasone, etoposide, ifosfamide, polymerase chain reaction, western blotting
Biological · Drug · Genetic
Lead sponsor
AIDS Malignancy Consortium
Network
Eligibility
18 Years to 120 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
17
States / cities
La Jolla, California • Los Angeles, California • Sacramento, California + 12 more
Conditions
Heavy Menstrual Bleeding, Bleeding Disorder, Von Willebrand Diseases
Interventions
Levonorgestrel Intrauterine System, Norethindrone Acetate
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
10 Years to 24 Years · Female only
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
9
States / cities
Palo Alto, California • Aurora, Colorado • Atlanta, Georgia + 5 more
Conditions
Smoking, Lung Neoplasms
Interventions
Integrated Fitness Assessment, Psychosocial Assessment and Care, Quality-of-Life Assessment
Other · Procedure
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Active, not recruiting Not applicable Interventional

upREACH Perinatal Home Visitation Program

NCT06133829
Conditions
Pregnancy, Postpartum
Interventions
upREACH Home Visitation Program
Behavioral
Lead sponsor
Baylor College of Medicine
Other
Eligibility
Female only
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Houston, Texas
Conditions
Medication Adherence
Interventions
Increasing Medication Adherence through Physician Incentives and Messaging
Other
Lead sponsor
National Bureau of Economic Research, Inc.
Other
Eligibility
65 Years and older
Enrollment
734 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Louisville, Kentucky
Completed Not applicable Interventional Accepts healthy volunteers Results available

Treatment of Periodontitis With Er:YAG Laser

NCT03628872
Conditions
Generalized Moderate Chronic Periodontitis, Generalized Severe Chronic Periodontitis, Periodontal Diseases
Interventions
Scaling and root planing, Er:YAG Laser, Hand instruments
Procedure · Device
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
New York, New York
Conditions
Spinal Cord Injury
Interventions
CSFD and elevation of MAP, Maintenance of MAP
Procedure
Lead sponsor
St. Joseph's Hospital and Medical Center, Phoenix
Other
Eligibility
18 Years to 75 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
3
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona
Conditions
Cocaine Addiction, Cocaine Abuse, Cocaine Dependence, Substance Abuse
Interventions
Placebo, Doxazosin
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years to 55 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Houston, Texas
Conditions
Obesity
Interventions
Phentermine 37.5 Mg, Dietary program, Exercise program
Drug · Behavioral
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years to 65 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Cleveland, Ohio
Conditions
Advanced Non-small Cell Lung Cancer
Interventions
paclitaxel poliglumex, pemetrexed
Drug
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Lebanon, New Hampshire
Conditions
Breast Cancer
Interventions
Tamoxifen, Lumpectomy, brachytherapy
Drug · Procedure · Radiation
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
18 Years and older · Female only
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2013
U.S. locations
1
States / cities
Minneapolis, Minnesota
Conditions
Vitiligo
Interventions
ARQ-252 cream 0.3%, ARQ-252 Vehicle cream, NB-UVB phototherapy active treatment, NB-UVB phototherapy sham treatment
Drug · Device
Lead sponsor
Arcutis Biotherapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
5
States / cities
San Diego, California • Coral Gables, Florida • Rolling Meadows, Illinois + 2 more
Conditions
Non-Small Cell Lung Cancer
Interventions
IMO-2055
Drug
Lead sponsor
EMD Serono
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
9
States / cities
Ocoee, Florida • Indianapolis, Indiana • Albany, New York + 6 more
Conditions
Solid Tumor
Interventions
IMGS-001
Drug
Lead sponsor
ImmunoGenesis
Industry
Eligibility
18 Years and older
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
13
States / cities
Gilbert, Arizona • Orange, California • Santa Monica, California + 10 more
Recruiting Not applicable Interventional Accepts healthy volunteers

Retraining and Control Therapy (ReACT) R33 Phase

NCT06007053
Conditions
Convulsion, Non-Epileptic
Interventions
ReACT, Supportive Therapy
Behavioral
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
11 Years to 18 Years
Enrollment
160 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
1
States / cities
Birmingham, Alabama
Conditions
Postoperative Pain, Inguinal Hernia
Interventions
Opioids, No opioids
Drug · Other
Lead sponsor
Clayton Petro
Other
Eligibility
18 Years and older
Enrollment
904 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
7
States / cities
Fountain Valley, California • Royal Oak, Michigan • Cleveland, Ohio + 3 more
Conditions
PTLD, Lymphoid Tumor, Hematopoietic/Lymphoid Cancer, Plasmacytic Hyperplasia PTLD, Infectious Mononucleosis, Florid Follicular Hyperplasia PTLD, Polymorphic PTLD, Monomorphic PTLD, Classical Hodgkin Lymphoma Type PTLD
Interventions
Rituximab, Brentuximab Vedotin, Bendamustine
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
2
States / cities
New Haven, Connecticut • Rochester, Minnesota